Grand Pharmaceutical Group (SEHK:512) - Aktienkurs, Nachrichten und Analyse

512 Aktienübersicht

Die Grand Pharmaceutical Group Limited, eine Investment-Holdinggesellschaft, ist in der Forschung und Entwicklung, der Herstellung und dem Verkauf von pharmazeutischen Präparaten und medizinischen Geräten, Biotechnologie- und Gesundheitsprodukten sowie pharmazeutischen Rohstoffen tätig.

Über das Unternehmen

512 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	3/6
Vergangene Leistung	2/6
Finanzielle Gesundheit	6/6
Dividenden	3/6

Belohnungen

60.8% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 13.9% pro Jahr

Risikoanalyse

Unbeständige Dividendenentwicklung

Grand Pharmaceutical Group Limited Wettbewerber

United Laboratories International Holdings

SEHK:3933

HK$15.0b

Simcere Pharmaceutical Group

SEHK:2096

HK$14.5b

China Medical System Holdings

SEHK:867

HK$16.1b

SSY Group

SEHK:2005

HK$12.5b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Grand Pharmaceutical Group
Historische Aktienkurse
Aktueller Aktienkurs	HK$4.65
52-Wochen-Hoch	HK$5.31
52-Wochen-Tief	HK$3.17
Beta	0.70
11 Monat Veränderung	-6.06%
3 Monate Veränderung	13.14%
1 Jahr Veränderung	5.20%
33 Jahre Veränderung	-35.06%
5 Jahre Veränderung	1.75%
Veränderung seit IPO	-82.12%

Aktuelle Nachrichten und Updates

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05

Recent updates

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12

We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Can Stay On Top Of Its Debt

Apr 26

Calculating The Fair Value Of China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512)

Apr 08

Here's Why We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Well Worth Watching

Mar 24

Aktionärsrenditen

	512	HK Pharmaceuticals	HK Markt
7D	-2.5%	-1.7%	-1.0%
1Y	5.2%	-7.7%	0.7%

Rendite im Vergleich zur Industrie: 512 übertraf die Branche Hong Kong Pharmaceuticals , die im vergangenen Jahr eine Rendite von -4.9 erzielte.

Rendite vs. Markt: 512 übertraf den Markt Hong Kong, der im vergangenen Jahr eine Rendite von -2.6 erzielte.

Preisvolatilität

Is 512's price volatile compared to industry and market?
512 volatility
512 Average Weekly Movement	4.6%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	7.0%
10% most volatile stocks in HK Market	14.9%
10% least volatile stocks in HK Market	3.7%

Stabiler Aktienkurs: 512 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: 512Die wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1995	10,534	Chao Zhou	www.grandpharm.com

Die Grand Pharmaceutical Group Limited, eine Investment-Holding, ist in der Forschung und Entwicklung, der Herstellung und dem Verkauf von pharmazeutischen Präparaten und medizinischen Geräten, Biotechnologie- und Gesundheitsprodukten sowie pharmazeutischen Rohstoffen tätig. Das Unternehmen bietet Produkte in den Bereichen Atemwegserkrankungen, Augenheilkunde, zerebro-kardiovaskuläre Notfälle und Biotechnologie an. Es produziert und vertreibt Produkte aus den Bereichen Pharmazeutika, Taurin, Agrochemikalien, chemische Medizin und Aminosäuren.

Grand Pharmaceutical Group Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Grand Pharmaceutical Group im Vergleich zum Marktanteil des Unternehmens?
512 grundlegende Statistiken
Marktanteil	HK$16.28b
Gewinn(TTM)	HK$1.88b
Umsatz(TTM)	HK$10.53b

8.7x

Kurs-Gewinn-Verhältnis

1.5x

Kurs-Umsatz-Verhältnis

Ist 512 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
512 Gewinn- und Verlustrechnung (TTM)
Einnahmen	HK$10.53b
Kosten der Einnahmen	HK$4.01b
Bruttogewinn	HK$6.52b
Sonstige Ausgaben	HK$4.64b
Umsatz	HK$1.88b

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.54
Bruttomarge	61.96%
Nettogewinnspanne	17.85%
Schulden/Eigenkapital-Verhältnis	21.7%

Wie hat sich 512 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

5.6%

Aktuelle Dividendenrendite

49%

Ausschüttungsquote

512 Aktienübersicht

Belohnungen

Risikoanalyse

Grand Pharmaceutical Group Limited Wettbewerber

SEHK:3933

HK$15.0b

SEHK:2096

HK$14.5b

SEHK:867

HK$16.1b

SEHK:2005

HK$12.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Recent updates

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Executive Chairman recently bought HK$271k worth of stock

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Executive Chairman recently bought HK$489k worth of stock

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Investor sentiment improved over the past week

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Less than half of directors are independent

Investor sentiment improved over the past week

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Executive Director recently bought HK$535k worth of stock

Upcoming dividend of HK$0.11 per share

Erträge & Einnahmen